 The FDA has approved Alnylam Pharmaceuticals Incs NASDAQ: ALNY Leqvio inclisiran to lower low-density lipoprotein cholesterol LDL-C. Leqvio is indicated in the U.S. as an adjunct to diet and maximally tolerated statin therapy to treat clinical atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia, requiring additional LDL-C lowering. 